Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy

Abstract

Aim: Triple negative breast cancer (TNBC) is known as aggressive subtype and have no identified targeted therapies. We examined the relationship of neoadjuvant chemotherapy response to genetic variations of TNBC.

Methods: The tumors used in this study were collected from Showa University Hospital, Japan. Thirteen formalin-fixed paraffin-embedded tumors from Japanese TNBC patients who underwent neoadjuvant chemotherapy were used for analysis. Of these, eight surgically resected tumors showed progressive disease and/or recurrence after treatment (PD/REC), and biopsy tissues from five patients showing pathological complete response (pCR) were analyzed. DNA extracted from tissue sample were analyzed. The Miseq system and Trusight Tumor Sequence panel kit were used to sequence 174 amplicons over 82 exons of 26 cancer-related genes to identify genetic mutations.

Results: Seven somatic non-synonymous variants were detected in three genes (FOXL2, PIK3CA, and TP53) in all five pCR patients, and six somatic non-synonymous variants in two genes (PTEN and TP53) were detected in six of eight PD/REC patients. Eight of 13 TNBC tumors were found to have TP53 pathogenic variants, in both pCR and PD/REC cases.

Conclusion: Although TP53 variation was detected in both pCR and PD/REC cases, each location and type of the variant were different. We could not identify genetic mutations associated with chemotherapy response and recurrence.

Keywords

Triple negative breast cancer / next generation sequence / TP53 and neo adjuvant chemotherapy

References

[1] Iwase H,Tsuda H,Kurosumi M.Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the Japanese Breast Cancer Society..Breast Cancer2010;17:118-24

[2] Foulkes WD,Reis-Filho.Triple-negative breast cancer..N Engl J Med2010;363:1938

[3] Dent R,Pritchard KI,Kahn HK.Triple-negative breast cancer: clinical features and patterns of recurrence..Clin Cancer Res2007;13:4429-34

[4] Lin NU,Hughes ME,Edge SB.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network..Cancer2012;118:5463-72 PMCID:PMC3611659

[5] Luangdilok S,Korphaisarn K.Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients..J Breast Cancer2014;17:376-85 PMCID:PMC4278058

[6] Liedtke C,Hess KR,Tordai A.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer..J Clin Oncol2008;26:1275-81

[7] Carey LA,Sawyer L,Moore DT.The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes..Clin Cancer Res2007;13:2329-34

[8] Lips EH,Savola SP,Oonk AM.Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness..Breast Cancer Res2011;13:R107 PMCID:PMC3262220

[9] Petitjean A,Kato S,Tavtigian SV.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database..Hum Mutat2007;28:622-9

[10] Lips EH,Hoogstraat M,Besselink NJ.Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response..Breast Cancer Res2015;17:134 PMCID:PMC4592753

[11] Balko JM,Wang K,Young CD.Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets..Cancer Discov2014;4:232-45 PMCID:PMC3946308

[12] Roy-Chowdhuri S,Routbort MJ,Singh RR.Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing..Am J Clin Pathol2015;144:713-21

[13] Olivier M,Carrieri P,Klaar S.The clinical value of TP53 gene mutations in 1794 patients with breast cancer..Clin Cancer Res2006;12:1157-67

[14] Langerød A,Borgan Ø,Bukholm IR.TP53 mutation status and gene expression profiles are powerful powerful prognositic markers of breast cancer..Breast Cancer Res2007;9:R30 PMCID:PMC1929092

[15] Ooe A,Noguchi S.Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers..Breast Cancer Res Treat2007;101:305-15

[16] Shiraishi K,Tanai C,Kuchiba A.Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer..J Clin Oncol2010;28:4945-52